All In Biotech

Drug Trial Radar · NCT07531095

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With ZL-1310 With or Without Anti-PD-L1 in Participants With Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Apr 21, 2026

Primary completion

May 21, 2028

Study completion May 21, 2031

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Apr 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.

Conditions

  • Small Cell Lung Cancer

Interventions

  • ZL-1310Drug

    ZL-1310 will be administered as an IV infusion.

  • TarlatamabDrug

    Tarlatamab will be administered as an IV infusion.

  • DurvalumabDrug

    Durvalumab will be administered as an IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 3.5 years
  2. Parts 1 and 3: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)Time frame: Up to Day 21

Locations

27 sites in 9 countries. Site status is shown where the registry gives one.

  • City of Hope Cancer Center Phoenix

    Goodyear, Arizona · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • City of Hope Chicago

    Zion, Illinois · Recruiting

  • Health Partners Cancer Center at Regions Hospital

    Saint Paul, Minnesota · Recruiting

  • New York University Cancer Institute

    New York, New York · Recruiting

  • Baptist Cancer Center

    Memphis, Tennessee · Recruiting

  • Next Virginia

    Fairfax, Virginia · Recruiting

  • Monash Medical Centre

    Clayton, Victoria, Australia · Recruiting

  • Institut Jules Bordet

    Brussels, Belgium · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • Ziekenhuis aan de Stroom Augustinus

    Wilrijk, Belgium · Recruiting

  • Centre Hospitalier Universitaire de Lyon Hopital Louis Pradel

    Bron, France · Recruiting

  • Hopital de la Timone

    Marseille, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Universitaetsklinikum Dresden

    Dresden, Germany · Recruiting

  • Universitaetsklinikum Wuerzburg

    Würzburg, Germany · Recruiting

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland · Recruiting

  • Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

    Gliwice, Poland · Recruiting

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Clinico Universitario Virgen de la Victoria

    Málaga, Andalusia, Spain · Recruiting

  • Hospital Universitari Vall d Hebron

    Barcelona, Catalonia, Spain · Recruiting

  • Hospital Clinico Universitario de Valencia

    Valencia, Valencia, Spain · Recruiting

  • Kantonsspital Sankt Gallen

    Sankt Gallen, Switzerland · Recruiting

  • Adana Sehir Egitim ve Arastirma Hastanesi

    Adana, Turkey (Türkiye) · Recruiting

  • Hacettepe Universitesi Tip Fakultesi Hastanesi

    Ankara, Turkey (Türkiye) · Recruiting

  • Izmir Ekonomi Universitesi Medical Point Hastanesi

    Izmir, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.